Clinical Trials Directory

Trials / Unknown

UnknownNCT02179775

Effect of "Sekanjabin e Safarjali" (Quince Oxymel) in the Prevention of Migraine Attacks

Comparison of Effectiveness of "Sekanjabin e Safarjali" (Quince Oxymel), Propranolol and Placebo in the Prevention of Migraine Attacks in Patients With Simultaneous Upper Gastrointestinal Dysfunction

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
45 (estimated)
Sponsor
Shiraz University of Medical Sciences · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether Quince Oxymel is effective in the prevention of Migraine attacks in patients with simultaneous upper gastrointestinal dysfunction.

Detailed description

This is a randomized, placebo-controlled, triple blinded clinical study to evaluate the effects of oral use of "Sekanjebin e Safarjali" (Quince Oxymel) in the Prevention of Migraine attacks in patients with simultaneous upper gastrointestinal dysfunction.45 patients with Migraine headache aged between 15-70, after taking signed informed consent, according to the International headache society criteria for headache \[2\] are included in this trial. 45 cases with Migraine headache with simultaneous upper gastrointestinal dysfunction will allocate to three arms by using simple randomization. Quince Oxymel, propranolol and placebo will be given as encoded, innominate bottles with the same shape and color. Quince oxymel and placebo will be prescribed as 10 cc, three times a day for 4 weeks. Frequency, duration and intensity of Migraine Attacks at the beginning time and during 4 weeks of trial, will be evaluated, as the primary outcome measures.

Conditions

Interventions

TypeNameDescription
DRUGpropranolol
DRUGQuince's oxymel
DRUGplacebo

Timeline

Start date
2014-07-01
Primary completion
2014-09-01
Completion
2014-10-01
First posted
2014-07-02
Last updated
2014-07-10

Locations

2 sites across 1 country: Iran

Source: ClinicalTrials.gov record NCT02179775. Inclusion in this directory is not an endorsement.